Drugs / QLF32101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05703204 | Feb 2023 → Aug 2024 | acute myeloid leukemia | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLF32101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05703204 ↗ |
| Route | Intravenous | “QLF32101 administered intravenously and subcutaneously” NCT05703204 ↗ |
| Route | Subcutaneous | “QLF32101 administered intravenously and subcutaneously” NCT05703204 ↗ |